Cipla Q1 Results: Cons profit drops 39% YoY to Rs 789 crore; revenue rises marginally

Pharma major Cipla on Thursday reported a net profit of Rs 789 crore for the first quarter of FY27, marking a sharp 39% decline from Rs 1,298 crore posted in the same quarter of the previous financial year. The net profit is attributable to the owners of the parent company.

The company’s revenue from operations remained largely unchanged at Rs 7,119 crore, up just 2.3% from Rs 6,957 crore reported in the corresponding quarter of the previous financial year, Cipla said in a regulatory filing.

Cipla's EBITDA (earnings before interest, tax, depreciation and amortisation) declined 33% year-on-year to Rs 1,192 crore in the first quarter compared to Rs 1,778 crore a year ago. The EBITDA margin for the quarter stood at 16.7%, down from 25.6% in the year-ago quarter.


Total tax expense declined to Rs 295 crore from Rs 478 crore last year, the company's regulatory filing showed.

On a sequential basis, however, net profit jumped 42% from Rs 555 crore in the fourth quarter of FY26. Revenue from operations rose 9% from Rs 6,541 crore in Q4.

Total expenses for the quarter came in at Rs 6,248 crore, up 14.7% from Rs 5,446 crore in the corresponding quarter of the previous financial year.

The company’s earnings per share Rs 9.77 compared to Rs 16.07 in the year-ago period. On a sequential basis, EPS improved from Rs 6.87.

Going ahead, investors will closely track the management's commentary on the generic drug tariff announced by US President Donald Trump, which is set to take effect from 2028.

Following the development, Cipla shares declined 3% to Rs 1,377 per share. In the last six months, the stock is up 6% but continues to trade 7% lower since the beginning of the year.